Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD. patients survived. Emerging data from current trials look promising and are 12 undergoing further study, however optimised supportive care remains the key to 13 reducing mortality from EVD. 14
are not ideal as they may lead to withholding of potentially beneficial 52 treatment (albeit experimental) from those with a condition that otherwise has 53 a very poor outcome.
[6] Using historical controls can circumvent this issue, 54 but calls into question the robustness of the study outcomes. Adaptive trial 55 designs where ongoing planned interim monitoring of the outcome data can 56 be used to alter the trial design after commencement to maximize the 57 potential benefit to study participants while maintaining statistical reliability, between multiple governmental and non-governmental healthcare glycoprotein specific antibodies, although it could not be concluded whether 100 higher vaccine doses would be required for optimal protection.
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Two further attenuated forms of rVSV: rVSVN4CT1GP1 and rVSVN1CT1GP3 102 were studied by Mire et al [13] , following concerns of developing arthritis in 103 some participants in prior trials [11] . None of the vaccinated experimental 104 animals (n=8) showed any signs of severe illness when exposed to lethal 105 challenge of EBOV.
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The advantages of the rVSV vaccine platforms include a shorter time to 
231
The above studies may be limited in their generalisability to human subjects.
232
The cohort numbers were low, which would also limit the power to detect rare • Dedicated staff health clinics given higher mortality rates among healthcare workers. [62] • Early involvement of patients and their carers with ongoing education and psychologic care
• Establish a survivor network for potential training and recruitment Mental health of healthcare workers (HCWs) must also not be neglected. 
